--- title: NIH, Gates Foundation Pledge $200 Million to Gene Therapy description: The NIH and the Gates Foundation will put $200 million toward developing gene therapies for HIV and sickle cell disease. canonical: https://time.com/5709297/nih-gates-foundation-gene-therapy/ author: Jamie Ducharme article:opinion: false article:content_tier: free article:published_time: 2019-10-24T16:48:44.000Z article:modified_time: 2026-02-24T07:37:58.118Z article:section: Health og:title: NIH, Gates Foundation Pledge $200 Million to Bring Gene Therapies to Patients Who Need Them Most og:description: Those in lower-income areas og:url: https://time.com/5709297/nih-gates-foundation-gene-therapy/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltd8ca08e56dbe0a65/698a04d2b21a9c406a502913/bill-gates-1.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 og:image:width: 1024 og:image:height: 576 og:image:alt: Bill Gates og:type: article twitter:card: summary_large_image twitter:title: NIH, Gates Foundation Pledge $200 Million to Bring Gene Therapies to Patients Who Need Them Most twitter:description: Those in lower-income areas twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltd8ca08e56dbe0a65/698a04d2b21a9c406a502913/bill-gates-1.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 ---  # NIH, Gates Foundation Pledge $200 Million to Bring Gene Therapies to Patients Who Need Them Most > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=c3d6f2e7-cf2f-46bc-8e93-d6a941f384de&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=c3d6f2e7-cf2f-46bc-8e93-d6a941f384de&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=c3d6f2e7-cf2f-46bc-8e93-d6a941f384de&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Oct 24, 2019 4:48 PM UTC  Bill Gates makes a speech at the Malaria Summit in London on April 18, 2018. Bill Gates makes a speech at the Malaria Summit in London on April 18, 2018. Jack Taylor—Getty Images  by [Jamie Ducharme](https://time.com/author/jamie-ducharme/)  ## Jamie Ducharme Ducharme is a contributor to TIME. Oct 24, 2019 4:48 PM UTC Some of the most cutting-edge — and effective — treatments in medicine are [unaffordable to the majority of people](https://time.com/collection/time-100-health-summit-2019/5703280/seema-verma-bernard-tyson-time-100-health/) who need them, with price tags sometimes exceeding $1 million. A new initiative from the [National Institutes of Health](https://time.com/5709207/medical-science-age-of-discovery/) (NIH) and the Bill & Melinda Gates Foundation is meant to change that unfortunate reality. Over the next four years, the NIH and the Gates Foundation will each invest $100 million toward developing gene-based cures for sickle cell disease and HIV, with a special focus on making these treatments available to the patients who need them most, the NIH [announced Wednesday](https://www.nih.gov/news-events/news-releases/nih-launches-new-collaboration-develop-gene-based-cures-sickle-cell-disease-hiv-global-scale). Both HIV and sickle cell disease — a group of inherited disorders that lead to abnormal red blood cell shape and function, potentially contributing to a number of possible complications — disproportionately affect those living in lower-income areas, namely Africa, and people of color, who in the U.S. are more likely than white Americans to struggle with poverty. “This unprecedented collaboration focuses from the get-go on access, scalability and affordability of advanced gene-based strategies for sickle cell disease and HIV to make sure everybody, everywhere has the opportunity to be cured, not just those in high-income countries,” NIH Director Dr. Francis Collins said in the NIH statement. “We aim to go big or go home.” Gene therapies, which alter genes in order to treat or prevent disease, have already yielded breakthroughs for highly difficult-to-treat conditions including [blindness](https://time.com/5073751/gene-therapy-visual-impairment/) and [leukemia](https://time.com/4921981/cancer-gene-threapy-fda/), but these treatments have been inaccessible to those in lower-resource countries, the statement says. The new initiative will first focus on developing gene-based treatments for sickle cell disease and HIV, then shift attention to accessibility. In terms of development, researchers have already zeroed in on potential pathways for gene-based treatments. For sickle cell disease, the statement says, a therapy could either correct the gene mutations that cause the disorder in the first place, or help the body achieve normal red blood cell function. For HIV, it could mean targeting infected DNA that lives inside a person’s cells, even if they are taking [antiretroviral treatment](https://time.com/5455488/future-of-hiv-treatment-pills/). Researchers are already working on potential cures for both [sickle cell disease](https://time.com/5642755/crispr-gene-editing-humans/) and [HIV](https://time.com/5544539/hiv-remission-london-patient/), but the new initiative could mean any breakthroughs that are achieved reach a much broader swath of the population. That said, the challenges of both developing and disseminating gene therapies are vast. “I’m not going to lie,” Collins told reporters on Wednesday. “This is a bold goal.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/5709297/nih-gates-foundation-gene-therapy/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5709297/nih-gates-foundation-gene-therapy/"},"headline":"NIH, Gates Foundation Pledge $200 Million to Bring Gene Therapies to Patients Who Need Them Most","datePublished":"2019-10-24T16:48:44.000Z","dateModified":"2026-02-24T07:37:58.118Z","description":"The NIH and the Gates Foundation will put $200 million toward developing gene therapies for HIV and sickle cell disease.","url":"https://time.com/5709297/nih-gates-foundation-gene-therapy/","keywords":["Research","onetime"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltd8ca08e56dbe0a65/698a04d2b21a9c406a502913/bill-gates-1.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Jamie Ducharme","jobTitle":"Ducharme is a contributor to TIME.","url":"https://time.com/author/jamie-ducharme/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltd8ca08e56dbe0a65/698a04d2b21a9c406a502913/bill-gates-1.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Bill Gates","caption":"Bill Gates","creditText":"Jack Taylor—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/research/","name":"Research"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5709297/nih-gates-foundation-gene-therapy/","name":"NIH, Gates Foundation Pledge $200 Million to Bring Gene Therapies to Patients Who Need Them Most"}}]}] ```